skip to content

Market News

PRTC says Akili opens enrolment for ADHD treatment

06 May 2016 07:47

PureTech Health notes that Akili Interactive Labs has announced open enrolment for its pivotal STARS-ADHD trial. The trial will evaluate the safety and efficacy of the company's proprietary platform, Project: EVO, for the treatment of children with ADHD.

Story provided by StockMarketWire.com

Related Company: PRTC

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

-

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.